References
Pece A, Milani P, Monteleone C, Trombetta CJ, De Crecchio G, Fasolino G, Matranga D, Cillino S, Vadalà M (2015) A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol 253:1867–1872. doi:10.1007/s00417-014-2886-x
Tan CS, Chew MC, Lim TH (2014) Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye (Lond) 28:17–22. doi:10.1038/eye.2013.204
Tan CS, Chew MC, Lim KH, Lim TH (2013) Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol 6:327–330. doi:10.3980/j.issn.2222-3959.2013.03.13
Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594–603. doi:10.1016/j.ajo.2010.10.030, e1
Isola V, Pece A, Parodi MB (2006) Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol 142:680–683. doi:10.1016/j.ajo.2006.04.028
Lee PY, Kim KS, Lee WK (2009) Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 53:52–56. doi:10.1007/s10384-008-0613-z
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Dr Tan receives research funding from the National Healthcare Group (Singapore) Clinician Scientist Career Scheme Grant (Code: CSCS/12005). Dr Tan also receives travel support from Bayer (South East Asia) Pte. Ltd., Heidelberg Engineering (Heidelberg, Germany), and Novartis (Singapore). These are not directly related to the subject matter or materials discussed in this manuscript. Dr Cheong, Dr Lim, and Mr Tan do not receive funding.
Conflict of interest
The authors report no conflicts of interest.
Rights and permissions
About this article
Cite this article
Tan, C.S., Cheong, K.X., Lim, L.W. et al. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol 254, 1433–1434 (2016). https://doi.org/10.1007/s00417-016-3284-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-016-3284-3